Cullinan Therapeutics, Inc. cotiza a 14.10 USD y tiene una capitalización bursátil de $867M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cel…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.81 | $-0.75 | $-0.77 |
| Estimado | $-0.84 | $-0.85 | $-0.84 | $-0.84 |
| Sorpresa | — | +4.7% | +10.7% | +8.3% |
| Métrica | CGEM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -53.8% | -40.4% | -13.4% |
| ROA | -49.0% | -32.0% | -17.0% |
| Current Ratio | 10.25 | 2.84 | +7.41 |
| Debt / Equity | — | 0.28 | — |